Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions
Current Oncology · 17.04.2026 · 33 (4) · 225
DOI: 10.3390/curroncol33040225 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 17.04.2026. Verfasst von Lucas Resende Salgado und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Non-muscle-invasive bladder cancer (NMIBC) represents approximately 78% of newly diagnosed bladder cancers and is characterized by high recurrence rates and variable progression risk. While transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains standard management, optimal treatment of high-risk and Bacillus Calmette-Guerin (BCG)-unresponsive disease remains controversial. Radiotherapy (RT), particularly in combination with chemotherapy, has been explored as a bladder-preserving alternative. Material and Methods: We conducted a narrative review of published literature evaluating the role of definitive RT in high-risk NMIBC, with emphasis on T1 disease. Retrospective series, prospective trials, meta-analyses, and contemporary guideline recommendations were examined. For each included study, we extracted data on the extent of TURBT (maximal vs. incomplete/non-specified), use and type of concurrent chemotherapy, radiotherapy technique (3D-conformal, IMRT, or proton), treatment volume (bladder only vs. whole pelvis), and dose/fractionation schedule.
Results
Early studies evaluating RT alone demonstrated modest complete response rates. More recent approaches incorporating maximal TURBT followed by concurrent chemoradiotherapy report improved outcomes, with complete response rates of approximately 80–88% and 5-year overall survival comparable to surgical series. The phase II NRG/RTOG 0926 trial in recurrent high-risk T1 disease after intravesical therapy failure demonstrated an 81% complete response rate and favorable bladder preservation outcomes. Meta-analytic data suggest 5-year recurrence-free survival around 54% and overall survival near 70%, although evidence remains limited and largely non-randomized. Advances in image-guided and hypofractionated RT may further improve therapeutic outcomes while limiting toxicity. Conclusions: while definitive chemoradiotherapy is a promising option for selected patients, it remains investigational and should be considered only in those who are unfit for or decline radical cystectomy. Prospective randomized studies are needed to better define its role in contemporary management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology and Radiology, Mount Sinai, New York, NY 10029, USA.
- Department of Urology, Northwell Health, New York, NY 11042, USA.
ORCID-Profile: Ahmed Rabie, Nicholas Murphy, Anthony Nehlsen, Kristin Hsieh, Kunal K Sindhu
Zitieren
APA
Resende Salgado, L., Zaytoun, O., Rabie, A., Murphy, N., Nehlsen, A., Hsieh, K., Dovey, Z., Aamir, A., & Sindhu, K. K. (2026). Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. Current Oncology, 33(4), 225. https://doi.org/10.3390/curroncol33040225
Vancouver
Resende Salgado L, Zaytoun O, Rabie A, Murphy N, Nehlsen A, Hsieh K, et al. Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. Current Oncology. 2026;33(4):225. doi:10.3390/curroncol33040225
BibTeX
@article{ResendeSalgado2026,
author = {Resende Salgado, Lucas and Zaytoun, Osama and Rabie, Ahmed and Murphy, Nicholas and Nehlsen, Anthony and Hsieh, Kristin and Dovey, Zachary and Aamir, Anum and Sindhu, Kunal K},
title = {Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {4},
pages = {225},
doi = {10.3390/curroncol33040225}
}
EUVIMED